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Abstract
We aimed to detect Attention-deficit/hyperactivity (ADHD) risk-conferring genes in adults. In children, ADHD is character-
ized by age-inappropriate levels of inattention and/or hyperactivity-impulsivity and may persists into adulthood. Childhood 
and adulthood ADHD are heritable, and are thought to represent the clinical extreme of a continuous distribution of ADHD 
symptoms in the general population. We aimed to leverage the power of studies of quantitative ADHD symptoms in adults 
who were genotyped. Within the SAGA (Study of ADHD trait genetics in adults) consortium, we estimated the single nucleo-
tide polymorphism (SNP)-based heritability of quantitative self-reported ADHD symptoms and carried out a genome-wide 
association meta-analysis in nine adult population-based and case-only cohorts of adults. A total of n = 14,689 individuals 
were included. In two of the SAGA cohorts we found a significant SNP-based heritability for self-rated ADHD symptom 
scores of respectively 15% (n = 3656) and 30% (n = 1841). The top hit of the genome-wide meta-analysis (SNP rs12661753; 
p-value = 3.02 × 10−7) was present in the long non-coding RNA gene STXBP5-AS1. This association was also observed in a 
meta-analysis of childhood ADHD symptom scores in eight population-based pediatric cohorts from the Early Genetics and 
Lifecourse Epidemiology (EAGLE) ADHD consortium (n = 14,776). Genome-wide meta-analysis of the SAGA and EAGLE 
data (n = 29,465) increased the strength of the association with the SNP rs12661753. In human HEK293 cells, expression of 
STXBP5-AS1 enhanced the expression of a reporter construct of STXBP5, a gene known to be involved in “SNAP” (Soluble 
NSF attachment protein) Receptor” (SNARE) complex formation. In mouse strains featuring different levels of impulsivity, 
transcript levels in the prefrontal cortex of the mouse ortholog Gm28905 strongly correlated negatively with motor impulsiv-
ity as measured in the five choice serial reaction time task  (r2 = − 0.61; p = 0.004). Our results are consistent with an effect 
of the STXBP5-AS1 gene on ADHD symptom scores distribution and point to a possible biological mechanism, other than 
antisense RNA inhibition, involved in ADHD-related impulsivity levels.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a com-
mon neurodevelopmental disorder affecting 2–5% of chil-
dren (Polanczyk and Rohde 2007) and 2.5–4.9% of adults 
(Franke et al. 2018). In children, ADHD is characterized 
by age-inappropriate, sustained symptoms of inattention 
and/or hyperactivity-impulsivity. In children and adults 
(Faraone et al. 2005) ADHD shows substantial heritability. 
Heritability  (h2) estimates are largely independent of the 
phenotypic measurement scale (i.e., categorical or con-
tinuous) and estimates are lower when using self-report 
rating scales (Franke et al. 2012). For clinically diagnosed 
ADHD, the genetic contribution to variation in ADHD 
was estimated at 72% in adult twins from the Swedish 
Twin Registry (n = 37,714) (Larsson et al. 2014), whereas 
the estimate was around 30% for the self-assessed ADHD 
index scored from the Conners’ Adult ADHD Rating 
Scales in a large (n = 12,594 subjects) Dutch sample of 
twins and their relatives (Boomsma et al. 2008).
For Attention Problems assessed by ASEBA (Achen-
bach System of Empirically Based Assessment; Achen-
bach et al. 2003) in 44,607 young and adult Dutch twins 
(57% with longitudinal data), there was a downward trend 
with age. Age to age correlations were age dependent and 
ranged from 0.33 (age 50–60+) to 0.73 (age 10–12). The 
stability across ages was explained by both genetic and 
environmental factors. Heritability at age three was 70% 
and remained high before age 12 (72–74%). After age 12, 
 h2 became 50–56% in adolescents, and this declined fur-
ther to 40–54% in adults (Kan et al. 2013). However, part 
of the decrease in  h2 may not be due to age but to differ-
ences in assessment (Kan et al. 2013, 2014).
A large Swedish study addressed the etiology of the 
association of the major dimensions of ADHD in adults 
and estimated that 52% of the correlation between inatten-
tive and hyperactive-impulsive symptoms was accounted 
for by genetic influences, and 48% by non-shared envi-
ronmental influences (n = 15,198 adult twin pairs) (Lars-
son et al. 2013). Shared genetic factors also underlie the 
increased risks for other psychiatric disorders adults with 
ADHD and their relatives, for example borderline per-
sonality disorder (Distel et al. 2011; Kuja-Halkola et al. 
2018) autism spectrum disorder (Ghirardi et al. 2018) and 
problem drinking (Derks et al. 2014). However, not all 
comorbidities are due to genetic risk; for the liability of 
attention-deficit/hyperactivity and tics and obsessive–com-
pulsive symptoms, the majority of genetic variance was 
specific rather than shared (Pinto et al. 2016).
The genetic contributions to ADHD in children and adults 
are complex, with multiple different genetic variants con-
tributing to the disorder (Faraone et al. 2015), both common 
and rare (Franke et al. 2012). Recently, 16 genome-wide 
associations have been established in an ADHD Genome-
Wide Association Studies meta-analysis (GWASMA) of 
childhood case-control studies from the psychiatric genom-
ics consortium (PGC) and The Lundbeck foundation initia-
tive for integrative psychiatric research (iPSYCH) (Demontis 
et al. 2018) and population-based samples from the early 
genetics and lifecourse epidemiology (EAGLE) consortium 
(Middeldorp et al. 2016). These studies estimated that the 
single nucleotide polymorphism (SNP)-based  h2 of ADHD 
symptom scores in children ranged from 5 to 34% in popu-
lation-based samples (EAGLE consortium) and was 21.6% 
in the PGC + iPSYCH case-control samples.
Inattention and hyperactivity–impulsivity symptoms can 
be reliably assessed in population-based cohorts based on 
rating scales. Phenotypic and genetic correlations between 
symptom scores assessed with the different instruments 
are substantial: in a clinical sample of 120 adults with 
ADHD the phenotypic correlation between the CAARS 
ADHD-index (Conners 1999) and the ADHD-RS, which 
obtains ADHD DSM-IV symptoms self-report was 0.73 
(p < 0.01) (Kooij et al. 2005). In 380 parents of children with 
ADHD, this correlation was of similar magnitude (r = 0.69; 
p < 0.001) (Thissen et al. 2012).As such, the disorder may 
be viewed being at the extreme end of normally distributed 
behavioral traits in the population (Larsson et al. 2013). This 
creates the possibility to collect large samples for gene-find-
ing studies.
Here, we aimed to identify genes associated with ADHD 
symptoms in adults from population-based and case-control 
cohorts in order to detect disease-relevant genes. Within 
the study of ADHD trait genetics in adults (SAGA) consor-
tium, we estimated the SNP-based  h2 of self-reported adult 
ADHD symptoms and subsequently carried out a GWASMA 
in nine cohorts of European-Caucasian origin (n = 14,689 
individuals, age 18 years or older). These samples included 
six population-based cohorts, two clinical ADHD samples 
and one clinical cohort ascertained for depressive and anxi-
ety disorders. We followed up the locus with the strongest 
statistical association in a replication analysis of quantita-
tive childhood ADHD symptom scores (n = 14,776) from the 
EAGLE consortium (Middeldorp et al. 2016). Genetic cor-
relations were estimated between the SAGA sample and the 
PGC + iPSYCH sample of children (Demontis et al. 2018) 
and between SAGA and the ADHD GWASMA results of 
the EAGLE consortium (Middeldorp et al. 2016). Finally, 
we conducted gene-based tests for genes with SNPs showing 
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a p-value < 1 × 10−6 in the meta-analysis, making use of 
the common SNPs from SAGA and rare variant data from 
the Erasmus Rucphen Family (ERF) study (see Table 1), 
included in SAGA.
Functional follow-up studies downstream of gene finding 
in ADHD, e.g. in model systems, to determine the biological 
relevance of a genetic finding are scarce (Klein et al. 2017). 
Core features of ADHD, inattention, hyperactivity, and 
impulsivity are well defined in mouse models (Loos et al. 
2014). Here we carried out functional follow-up studies for 
the gene with the top association result from the GWASMA 
in three mouse inbred strains with large differences in motor 
impulsivity derived from reaction time tasks, and in a human 
cell assay.
Methods
Study populations in the SAGA consortium
ADHD symptom scores in adults were available in nine 
cohorts of European descent (please see references in 
Table 1; Supplementary Table 1; Supplementary Fig. 4).
(1) The Netherlands Twin Registry (NTR) is a popula-
tion-based longitudinal cohort of twins and their fam-
ily members, e.g. parents, siblings, spouses, which 
recruited (young) adult twins in the early 1990s through 
city council registrations. Continued recruitment of 
adult twins took place continuously via the NTR web-
site and e.g. via media campaigns. Twin families are 
followed longitudinally through survey studies and 
biobank projects.
(2) The Netherlands Study of Depression and Anxiety 
(NESDA) is an ongoing longitudinal naturalistic cohort 
Table 1  Information on cohorts and phenotype assessment in the SAGA consortium included in the GWASMA
F female, CAARS ADHD-index Conners’ Adult ADHD Rating Scale, ADHD-RS DSM-IV ADHD Rating Scale, ASR ADHD Attentional Deficit/
Hyperactivity Problems subscale from the Adult Self Rating
a Untransformed values observed per cohort
b Only affected individuals included
Cohort name N (% F) Age (SD) Symptom list (N 
items)
Score  rangea Mean score (SD)a Sample type References
Netherlands twin 
registry (NTR)
5935 (63%) 43.7 (15.2) CAARS ADHD-
index (12)






1977 (66%) 46.5 (13.0) CAARS ADHD-
index (12)








1043 (53%) 45.6 (13.3) CAARS ADHD-
index (12)
0–25 7.8 (4.4) Population-based Aulchenko et al. 
(2004)
NeuroIMAGE 470 (51%) 42.3 (5.3) ADHD-RS (23) 0–43 14.1 (8.9) Parents of children 
of ADHD















113 (63%) 37.7 (11.5) ADHD-RS (23) 1–18 12.04 (3.3) Clinical population 














1215 (48%) 19.0 (0.6) ASR ADHD (13) 0–26 5.9 (4.4) Population-based Oldehinkel et al. 
(2015)
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study of 2981 people, aged 18–65 years at baseline, 
with lifetime and/or current depressive and/or anxi-
ety disorders (n = 2329, 78%) and healthy controls 
(n = 652, 22%). Participants were recruited from the 
community (n = 564, 19%), primary care (n = 1610, 
54%) and specialized mental healthcare (n = 807, 27%) 
from September 2004 to February 2007 at three study 
sites (Amsterdam, Groningen, Leiden). Exclusion cri-
teria were: (a) having a primary clinical diagnosis of 
psychotic disorder, obsessive–compulsive disorder, 
bipolar disorder or severe addiction disorder, and (b) 
not being fluent in Dutch.
(3) The TRacking Adolescents’ Individual Lives Survey 
(TRAILS) is an ongoing, multidisciplinary research 
project on the psychological, social and physical 
development of adolescents and young adults. More 
than 2500 young people participate, since their tenth 
or eleventh year of age. These participants have been 
examined every 2–3 years for the past 15 years, through 
questionnaires, interviews, tests and/or physical meas-
urements. Information is provided by youngsters, fam-
ily members, teachers and partners.
(4) Erasmus Rucphen Family (ERF) is a family-based 
cohort originating from 22 couples and spread over 
23 generations. All descendants of those couples were 
invited to visit the clinical research center in the region, 
where they were examined in person and interviewed 
on a broad range of topics, including medication use 
and medical history.
(5) International Multicenter ADHD Genetics (NeuroIM-
AGE) collected DNA and information on ADHD and 
relevant comorbidities from families with (at least) one 
child diagnosed with ADHD between 2003 and 2007. 
The Dutch site of the IMAGE project also collected 
other (cognitive and behavioral) measures on (unaf-
fected) parents. The behavioral information on the 
parents was used in this study.
(6) The Brain Imaging Genetics (BIG) study is a popu-
lation-based study of healthy individuals (age range 
18–45  years) who participated in imaging studies 
carried out in the Donders Institute, in Nijmegen, the 
Netherlands. The assessment of ADHD symptoms was 
performed through internet-based testing, as part of an 
electronic questionnaire and test battery.
(7) The Nijmegen Biomedical Study (NBS) is a population-
based study that was initiated in 2000 in Nijmegen in 
the eastern part of The Netherlands. Eligibility criteria 
were age 18 years or older, not living in an institution 
or rest home and the ability to fill out a questionnaire 
in Dutch. Participants were invited to fill out a postal 
questionnaire (NBS-1 QN) and to donate a blood sam-
ple. Psychological problems and symptoms for ADHD 
were collected in the second wave of the study (NBS-
2), that was initiated in 2005.
(8) The International Multicenter persistent ADHD Col-
laboraTion (IMpACT) included patients and healthy 
controls recruited at the department of psychiatry, 
Radboud University Medical Center, Nijmegen and 
through advertisements. Patients were included if they 
had previously been diagnosed with persistent ADHD, 
i.e. present since childhood, by a psychiatrist according 
to the DSM-IV-TR. Exclusion criteria were psychosis, 
addictions in the last 6 months, current Major Depres-
sion Disorder, full-scale IQ estimate < 70, neurologi-
cal disorders, sensorimotor disabilities, medication use 
other than psychostimulants, atomoxetine or bupropion 
and failure to withhold stimulant medication 24 h prior 
to testing. These same criteria were applied to the Neu-
roIMAGE sample.
(9) The Vall d’Hebron institute de recerca (VHIR) sam-
ple consisted of ADHD cases only. Participants were 
referred to the program from primary care centres, 
children’s neuropsychiatric surgeries or mental health 
hospitals in Barcelona, Spain because of a diagnostic 
suspicion of ADHD. The diagnosis of ADHD was eval-
uated with the structured clinical interview for DSM-
IV (SCID-I) and the conners adult ADHD diagnostic 
Interview for DSM-IV (CAADID-II).
ADHD symptom scores in the SAGA consortium
ADHD symptom scores were assessed by three instruments 
(see Table 1). First, the ADHD-index of the Conners Adult 
ADHD Rating Scale (CAARS ADHD-index) (Conners 
1999) which consists of 12 items, scored on a 4-point scale 
(0 = never, 3 = very often; see Supplementary Table 8 for 
details). The CAARS ADHD-index (used in NESDA, NTR, 
ERF) is an extensively tested psychometric instrument with 
high internal consistency and reliability.
Second, the total scores of the DSM-IV ADHD Rating 
Scale (ADHD-RS) (Kooij et al. 2005). Five cohorts (Neuro-
IMAGE, BIG, IMpACT, VHIR, NBS) collected information 
using the ADHD-RS (Kooij et al. 2005), which has high 
validity in population-based and case samples. Subjects were 
asked to complete the ADHDRS for current symptoms in 
adults. Symptoms were reported over the last 6 months. Par-
ticipants had to answer 23 questions on a four-point scale 
(never, sometimes, often, very often). The 23 current item 
scores were recalculated to the original 18 DSM-IV-TR 
ADHD criteria.
Third, the Attentional Deficit/Hyperactivity Problems 
subscale from the adult self report (ASR ADHD; 13 items) 
(Achenbach et al. 2003) was used by one cohort, TRAILS. 
The ASR ADHD scale has 13 items; response format is 0, 1, 
and 2 per item. Possible range in scores 0–26. In TRAILS, 
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GWAS analyses were done with the phenotype measured at 
the level of the item average rather than the item sum.
Genetic variant calling and quality control 
in the SAGA consortium
An overview of genome-wide SNP genotyping, quality 
control, and imputation is given in Supplementary Table 1. 
Exomes of 1336 individuals from the ERF population, 
which is a genetically isolated population in the Netherlands 
(Aulchenko et al. 2004), were sequenced (see Supplemen-
tary Methods), and ADHD index data were available for 
587 of these individuals. Detection of rare variants in the 
ERF study was done for genes harboring SNPs with associa-
tion p < 1 × 10−5 in the GWASMA, and variants identified 
in these exomes were used to estimate the contribution of 
rare variants in the genes of interest to ADHD behavior (see 
Supplementary Methods).
GCTA 
Genome-wide Complex Trait Analysis (GCTA) (Yang 
et al. 2011) was used to compute the variance in the ADHD 
symptom score explained by common SNPs in the two larg-
est cohorts included in the SAGA meta-analysis, the NTR 
and NESDA (n > 1500 unrelated subjects, we selected one 
random sibling per twin pair across all pairs). A genetic 
relationship matrix (GRM) for all individuals in the dataset 
was estimated based on SNPs with high imputation quality 
(see Supplementary Methods). Bivariate GCTA (Yang et al. 
2011) was additionally run on the CAARS ADHD-index 
and ASR-ADHD data also available in the NTR cohort, to 
assess the genetic correlation  (rg) between the two diagnostic 
instruments.
Genome‑wide association and meta‑analysis 
in the SAGA consortium
GWAS was conducted in each cohort by linear regression 
under an additive model. Age was included as a covariate, 
but not gender, which was not significantly associated with 
the ADHD scores in any study. Four principal components 
were added to account for possible population stratification 
effects. Information on software packages is provided in 
Supplementary Table 1. In all analyses, the uncertainty of 
the imputed genotypes was taken into account depending 
on the genotyping array and imputation software (threshold 
used: 0.8 < INFO < 1.1, RSQR ≥ 0.6, INFO ≥ 0.6; see Sup-
plementary Table 1). Location of SNPs reported is from the 
build 37 (hg19) 1000G data. Meta-analysis was conducted 
in METAL (http://www.sph.umich .edu/csg/abeca sis/metal /
index .html) by the p-value-based method, given the intrin-
sic variability of the quantitative traits used that limits our 
ability to combine betas and standard errors freely. While 
the trait scores used in the different GWAS are correlated, 
we cannot be completely sure that the sampling distribution 
of these traits is exactly the same (see Supplementary Meth-
ods). The meta-analysis was performed in the full sample 
(nine cohorts) and restricted to the population-based samples 
(seven cohorts; “restricted sample”).
Replication in the EAGLE consortium
Within EAGLE, association of ADHD-related measures 
was assessed in nine population-based childhood cohorts 
with genotype data imputed against the 1000 Genomes ref-
erence panel (Middeldorp et al. 2016). Linear regression 
of the phenotype on sex, age, genotype dose, and principal 
components was performed in all cohorts, followed by meta-
analysis based on p-values in METAL. The TRAILS cohort 
is part of both consortia, and was excluded from the EAGLE 
consortium for replication analysis, leaving a total of 14,776 
children from eight cohorts.
Lookup of significant GWAS Loci
Evidence for an effect of the 12 independent ADHD-
associated SNPs from the PGC + iPSYCH GWASMA on 
adult ADHD symptoms was studied through a look-up of 
results. Linkage disequilibrium (LD)-independent loci with 
corresponding index-SNPs were obtained from Table 1 of 
Demontis et al. (2018). If the index variant was not pre-
sent in the SAGA data set, a proxy variant was selected 
using LDlink (https ://analy sisto ols.nci.nih.gov/LDlin k/). 
The Bonferroni-corrected significance level was set at 
p = 0.05/12 = 0.00417.
Linkage disequilibrium score regression (LDSR) 
analysis
LDSR was used to estimate the genetic correlation between 
the PGC + iPSYCH sample of children (Demontis et al. 
2018) the SAGA sample of adults and the ADHD GWASMA 
data of the EAGLE consortium. Each dataset underwent 
additional filtering for markers overlapping with HapMap 
Project Phase 3 SNPs, INFO score ≥ 0.9 (where available), 
and MAF ≥ 1%. Indels and strand-ambiguous SNPs were 
removed. LDSR analysis was performed using the LDSR 
package (https ://githu b.com/bulik /ldsc (Bulik-Sullivan et al. 
2015), see Supplementary Methods).
Gene‑based analysis of common and rare variants
Genes containing SNPs with p-values < 1 × 10−6 in the meta-
analysis of the nine cohorts were selected for gene-based 
tests using common and rare variants. The common variant 
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analysis was performed in MAGMA (de Leeuw et al. 2015). 
Flanking regions of 25 kb for each gene were included in the 
analyses. The rare variant analysis was performed with the 
sequence kernel association test (SKAT; only in the ERF 
study) library of the R-software (Wu et al. 2011). Only char-
acterized genes plus the STXBP5-AS1 gene were analyzed.
Functional analyses
Follow-up functional analyses were performed on the 
STXBP5-AS1 locus containing the best association p-value 
in the SAGA full sample GWASMA. Given that the 
STXBP5-AS1 gene, which contains the top hits, is hitherto 
uncharacterized, we investigated its function. STXBP5-AS1 
encodes a long noncoding RNA (lncRNA). Although human 
STXBP5-AS1 does not have any orthologues listed in the 
UniGene database, it is conserved in primates and shows 
a modest conservation in rodents (Supplementary Table 7 
and alignment in Supplemental Fig. 2). In the hg19 genome 
release annotation STXBP5-AS1 is located next to STXBP5 
in the opposite orientation, with antisense sequence overlap 
in exon one of STXBP5 (Fig. 1a). It may be hypothesized 
that STXBP5-AS1 affects STXBP5 expression. For such natu-
ral antisense RNAs, both repression and enhancement of the 
expression of cognate genes have been described (Kimura 
et al. 2013; Matsui et al. 2008). We tested this hypothesis 
by designing a reporter gene fusing exon 1 of STXBP5 to 
EGFP, and quantifying its expression in human HEK293 
cells. Human STXBP5-AS1 encodes multiple splice vari-
ants, many of which lack a region that overlaps the STXBP5 
gene. To test for regulatory effects of STXBP5-AS1 on the 
expression of STXBP5, a fluorescent reporter construct was 
designed to contain the region of antisense overlap (see Sup-
plementary Methods).
Mouse models
According to current annotation in GRCm38.p6, the mouse 
lncRNA gene Gm28905 shares sequence similarity with 
human STXBP5-AS1 but lacks antisense overlap with mouse 
Stxbp5. Nonetheless, we use the annotation Stxbp5-AS1 
next to the official gene name. Given the in vitro effects 
Fig. 1  STXBP5-AS1 positively regulates the expression of its cog-
nate mRNA. a Top: Design of two reporter constructs. Top: Exon 1 
of human STXBP5, containing the natural 5′UTR and encoding the 
first 50 amino acids, was fused in-frame to EGFP. The STXBP5-AS1 
transcript including the region showing perfect (100%) sequence 
overlap with the encoded STXBP5 transcript is depicted schemati-
cally in blue. Bottom: To control for transfection efficiency and dif-
ferences in cellular metabolic rates, we co-expressed a non-target 
mRNA comprised of human HPRT1 exon 1 fused to mCherry. b 
Typical examples of HEK293 cells expressing both constructs with 
or without STXBP5-AS1. c Quantitation of EGFP and mCherry fluo-
rescence in presence or absence of STXBP5-AS1 (947 and 974 cells 
respectively). d, e The ratio of STXBP5-EGFP and HPRT1-mCherry 
was calculated for each cell. Data are presented as a histogram d or as 
mean ± SEM e. ***p = 6 × 10−51;  t946 = 4.4412, Student’s t-test
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on STXBP5-EGFP protein expression, we tested the rela-
tionship between gene expression of both mouse Stxbp5 
and/or Gm28905 / Stxbp5-AS1 and measures of behavio-
ral impulsivity. We analyzed gene expression in medial 
prefrontal cortex of three mouse inbred strains previously 
described to have large differences in motor impulsivity 
(Loos et al. 2014). RNA was derived from prefrontal cor-
tex of adult male mice from the inbred strain C57BL/6J 
(n = 8) and recombinant inbred strains BXD29 (n = 8) and 
BXD68 (n = 7), and gene expression was quantitated (see 
Supplementary Methods). For one C57BL/6J animal the 
RNA isolation failed, and for one BXD68 animal we did 
not have behavioral data; hence, the n-numbers vary between 
analyses. Strains were bred in the facility of the Neuro-Bsik 
consortium of the VU University (Amsterdam, The Nether-
lands) and used for behavioral analyses (Loos et al. 2014; 
Spijker et al. 2004).
Results
ADHD symptom scores phenotypic characterization
Quantitative assessment instruments are listed in Table 1. 
The quantitative phenotypes showed a weak, negative cor-
relation with age and no association with gender in any 
cohort. We estimated the phenotypic correlation between 
the CAARS ADHD-index and the ASR-ADHD in the NTR 
(n = 15,226; average age 40 years, SD = 16.1) to be 0.67 
(p < 0.0001). In younger participants in the age range of the 
TRAILS cohort (18–22 years, n = 2687), the correlation was 
similar (r = 0.68, p < 0.0001).
Genetic correlations of ADHD symptom scores
A significant SNP-based heritability was estimated for 
the CAARS ADHD-index in a subsample of each of the 
two largest cohorts: 30% (SE = 16.7%, p = 0.035) in 
NESDA (n = 1841 unrelated subjects) and 15% (SE = 7.8%, 
p = 0.020) in NTR (n = 3881 unrelated participants). Both 
estimates are significant, but given the sample sizes in each 
cohort, they are not statistically different from each other. 
We also estimated the genetic correlation for the CAARS 
ADHD-index and the ASR-ADHD using bivariate GCTA. In 
all individuals from the NTR with genotype and phenotype 
data (n = 6036 related and unrelated subjects), the genetic 
correlation was 0.818 (SE = 0.256). When analyzing the 
bivariate data in 2921 unrelated subjects, the point estimate 
of the genetic correlation was 0.813 (SE = 0.364).
We estimated the genetic correlation between 
PGC + iPSYCH and the complete SAGA sample to be 
0.541 (SE = 0.447, p = 2.26 × 10−1; the VHIR cohort pre-
sent in both studies). The SNP-based heritability of the 
complete SAGA samples, assessed by LDSR, was 0.0183 
(SE = 0.038). The genetic correlation between the com-
plete SAGA sample and the childhood ADHD cohort of the 
EAGLE-ADHD consortium was modest and non-significant 
 (rg = 0.2959, SE = 1.2906, p = 0.8187).
In NTR and NESDA, a subset of participants (n = 6678) 
had additional phenotype data on hyperactivity/impulsivity 
and inattention symptom subscales of the CAARS available. 
These scales of each nine items are non-overlapping with 
the 12 ADHD-index items (see Supplementary Table 8). 
For hyperactivity/impulsivity symptoms, the p-value for 
association with rs12661753 was 1.51 × 10−5, whereas for 
inattention it was 3.53 × 10−2, suggesting a differential effect 
of the variant between hyperactivity and impulsivity but we 
cannot claim that this is a significant difference between the 
two traits.
Genome‑wide association, meta‑analysis 
and replication
For the nine separate GWAS (in the SAGA Consortium), the 
genomic control inflation factors (lambda) ranged between 
0.960 and 1.027 (mean lambda 0.999, Supplementary 
Table 2). Meta-analysis (Fig. 2a) of the full sample revealed 
the lowest p-value (3.02 × 10−7) for the intronic SNP 
rs12661753 in STXBP5-AS1 (Supplementary Fig. 3E); for 
the meta-analysis of the restricted sample, p-value for this 
SNP was 1.48 × 10−6 (Fig. 2b). Replication was observed 
for rs12661753 (p = 3.07 × 10−2) for childhood ADHD 
symptoms in the EAGLE-ADHD consortium (Middeldorp 
et al. 2016). The subsequent GWASMA between SAGA and 
EAGLE revealed the best association p-value = 2.05 × 10−7 
for SNP rs12664716 (n = 29,465; Supplementary Fig. 3F) 
located in the STXBP5-AS1 gene, and in high LD (D′ = 1.0, 
 r2 = 0.98) with rs12661753  (PSAGA−EAGLE=3.55 × 10−7; 
Fig. 2c).
The index variant rs12661753 was not associated with 
ADHD risk in the recent case-control PGC + iPSYCH 
GWASMA of ADHD in a sample mainly consisting of chil-
dren (p = 0.6316, n = 55,374). A look-up of genome-wide 
significant ADHD index SNPs from this PGC + iPSYCH 
GWASMA for association in the SAGA consortium also 
revealed no significant associations with adult ADHD symp-
toms (Supplementary Table 6).
As shown in Table 2 and Supplementary Table 3, eight 
independent clumped loci (including 50 common variants) 
showed p-values < 1 × 10−6. Of these, four were also amongst 
the top-associated loci from the restricted SAGA GWASMA 
(no patients; Supplementary Table 4). The genes closest to 
these SNPs were selected for gene-based analysis (Table 2). 
Analysis of common variants in seven genes (plus 25 kb 
flanking regions) in the SAGA GWASMA showed signifi-
cant association with ADHD symptoms. Three significant 
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Fig. 2  Manhattan & QQ plot of the ADHD Symptom Total Score 
meta-analysis from the complete SAGA consortium (Panel a), with-
out patients (Panel b) and meta-analysis from the SAGA & EAGLE 
consortia (Panel c). a Manhattan & QQ plot of the ADHD symptom 
total score meta-analysis from the complete SAGA consortium. Asso-
ciation p-values > 0.05 in the GWAS plot are not shown. All p-values 
are shown in the QQ-plot. b Manhattan & QQ plot of the ADHD 
Symptom Total Score meta-analysis from the SAGA consortium 
without patient cohorts. Association p-values > 0.05 in the GWAS 
plot are not shown. All p-values are shown in the QQ-plot. c Man-
hattan & QQ plot of the ADHD Symptom Total Score meta-analysis 
from the SAGA & EAGLE consortia
Table 2  Most strongly associated (clumped) SNPs (p-value < 1 × 10−6) coming from the meta-analysis of nine cohorts from the SAGA consor-
tium in physical position order (hg19)
SNPs organized on association p-values. *bp position based on the GRCh37.p13 build; Allele frequency of tested allele based on n = 14,689





rs12661753 6 6q24.3 147409235 3.02 × 10− 7 A/G 0.962 STXBP5-AS1
rs1564034 2 2p25.2 6510305 2.15 × 10− 6 T/G 0.670 LINC01247
rs1930272 1 1p31.1 83491910 4.75 × 10− 6 T/C 0.544 LOC107985037
rs28734069 4 4q26 120042409 5.77 × 10− 6 T/C 0.016 LOC102723967; LOC105377395
rs13274695 8 8p23.2 3723378 6.00 × 10− 6 A/G 0.077 CSMD1; LOC105377790
rs73204517 13 13q21.33 69920315 7.19 × 10− 6 C/G 0.126 Downstream LINC00383
rs11209188 1 1p31.3 68455306 7.88 × 10− 6 A/G 0.534 GNG12-AS1
rs2189255 8 8q21.3 91190297 9.61 × 10− 6 T/C 0.703 CALB1; LINC00534
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findings (p < 0.007) were for the STXBP5-AS1, LINC01247 
and the LINC00534 genes. Nominal significant associations 
(p < 0.05 gene-based) were seen for, CALB1, GNG12-AS1, 
STXBP5 (Supplementary Table 5). It is important to note 
that STXBP5 and STXBP5-AS1 have no physical separation, 
thus their 25 kb flanking regions overlap (STXBP5 is located 
on the forward [“+”] and STXBP5-AS1 on the reverse [“-”] 
strand—see Supplementary Figs. 3E, F). The rare variant 
analysis also showed nominal association for STXBP5. 
For four genes (GNG12-AS1, LINC01247, STXBP5-AS1, 
LINC00534), rare variants were not observed/detected (Sup-
plementary Table 5).
Functional analysis
Expression of the antisense lncRNA variant STXBP5-
AS1-003 (containing the overlap with STXBP5) caused an 
increase in the fluorescence ratio between STXBP5-EGFP 
and the control (Fig. 1b–e).
Mouse models
We confirmed the recombinant inbred (RI) strain differ-
ence in motor impulsivity between the BXD68, BXD29, 
and C57BL/6J strains (Kruskal–Wallis, p = 0.006), meas-
ured as premature responses in the 5-choice serial reaction 
time task (Loos et al. 2014). In addition, these RI strains 
showed differences in the attention parameter of errors 
of omission  (F2,19 = 4.98, p = 0.018), but not the attention 
parameter of percentage correct responses  (F2,19 = 0.32, 
p = 0.733) (Fig. 3a). In these mice, we detected expres-
sion of Gm28905 / Stxbp5-AS1 lncRNA in the prefron-
tal cortex by real-time quantitative PCR, which differed 
across strains  (F2,19 = 11.53; p = 0.001). This transcript 
showed lowest expression in the most highly impul-
sive strain, BXD68 (BXD68: 4.58 ± 0.11, C57BL/6J: 
5.25 ± 0.14, BXD29: 5.19 ± 0.07, Bonferroni-corrected 
post-hoc PBXD68 vs C57BL/6J = 0.001; PBXD68 vs BXD29 = 0.002) 
(Fig. 3b). Expression of Stxbp5 mRNA was not different 
between the three strains (BXD68: 9.89 ± 0.09; C57BL/6J: 
9.83 ± 0.04; BXD29: 9.99 ± 0.08;  F2,19 = 1.23; p = 0.314). 
These results suggest that Gm28905 / Stxbp5-AS1 affects 
impulsivity independent of the Stxbp5 transcript. Examin-
ing correlations between Gm28905 / Stxbp5-AS1 transcript 
level and impulsivity/(in)attention measures, we found a 
significant correlation with motor impulsivity (Spearman’s 
rho = − 0.61; p = 0.004; BCa − 0.15 to − 0.85) that with-
stood Bonferroni correction (threshold p-value < 0.008). A 
nominally significant association was found for expression 
of Gm28905/Stxbp5-AS1 with attention, when measured 
as errors of omission (Guillem et al. 2011) (Spearman’s 
rho = 0.51; p = 0.019; BCa 0.01–0.86), but not when meas-
ured as percentage correct responses (Pearson r = 0.31; 
p = 0.178; BCa − 0.08–0.61). Expression of Stxbp5 did not 
correlate with any of these parameters (Fig. 3c).
Discussion
We report a genome-wide association meta-analysis with 
three different but correlated adult ADHD symptom lists in 
nine European adult population-based and case-only cohorts 
(n = 14,689 individuals). The STXBP5-AS1 locus (best SNP 
p = 3.02 × 10−7) was the most strongly associated in this 
meta-analysis. This association was replicated in the EAGLE 
meta-analysis (PEAGLE = 2.89 × 10−2), and the top-hit from 
the full SAGA-EAGLE GWASMA was also located in the 
STXBP5-AS1 gene and in almost perfect LD with the origi-
nal finding (SNP rs12664716, PSAGA−EAGLE = 2.05 × 10−7; 
n = 29,465).
For the adult ADHD-index, an earlier large twin fam-
ily study estimated total  h2 at 30%. For clinically assessed 
adult ADHD as well as for total sum scores for Attention 
Problems the  h2 estimates were even higher, as summarized 
in the introduction. Common SNPs thus are hypothesized 
to contain substantial information concerning the genetic 
variance underlying adult ADHD and Attention Problems. 
The SNP-based heritability analyses, which were ran prior 
to GWASMA, provided estimates of 15–30% explained vari-
ance of adult ADHD symptom scores in the general popu-
lation. Such estimates are comparable with the estimates 
obtained for ADHD and four additional categorically defined 
psychiatric disorders (Psychiatric Genomics Consortium 
et al. 2013), providing rationale for a gene-finding enterprise 
for adult ADHD symptoms in the general population. The 
significant SNP-based heritability and the considerable phe-
notypic and genetic correlations between assessment instru-
ments support the validity of our meta-analysis approach of 
GWA results obtained across contributing data sets.
The function of the STXBP5-AS1-encoded lncRNA is 
currently unknown. STXBP5-AS1 has been proposed as a 
prognostic biomarker for survival of cancer patients (Guo 
et al. 2016), but no information is available for its role 
in ADHD, related traits, or other psychiatric diseases. In 
humans it overlaps in anti-sense with STXBP5, encoding 
a protein involved in synaptic function by regulating neu-
rotransmitter release through stimulating SNARE complex 
formation (Sakisaka et al. 2008; Yizhar et al. 2004). This 
complex plays a major role in intracellular vesicular traf-
ficking in eukaryotic cells and is involved in the exocytotic 
release of neurotransmitters during synaptic transmission 
(Antonucci et al. 2016). Genes related to the SNARE com-
plex and its regulators have been investigated in ADHD 
(Bonvicini et al. 2016), and current results suggest that this 
complex may exert distinct roles throughout development, 
with age-specific effects of its genetic variants on ADHD 
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behavior (Cupertino et al. 2016). Specifically, deletions 
and mutations of STXBP5 occur in autism (Davis et al. 
2009) and epilepsy (Dhillon et al. 2011). STXBP5 has a 
presynaptic role that negatively regulates neurotransmitter 
release by forming syntaxin-SNAP25-tomosyn complex 
(Sakisaka et al. 2004). However, the postsynaptic role of 
STXBP5 has not been elucidated well.
Post-hoc analysis suggested that STXBP5-AS1 could 
significantly affect both hyperactivity-impulsivity and inat-
tention. We were able to determine that both hyperactivity/
Fig. 3  Prefrontal cortex gene expression of mouse Gm28905 / 
Stxbp5-AS1 is correlated with impulsivity. a Mouse RI strains 
BXD68 (red, n = 6), C57BL/6J (black, n = 8) and BXD29 (blue, n = 8) 
were selected based on a difference in premature responses (motor 
impulsivity; Bonferroni-corrected post-hoc BXD68 vs. BXD29, 
p = 0.005; C57BL/6J vs. BXD29, p = 0.122) and the attention param-
eter of error of omissions (Bonferroni-corrected post-hoc BXD68 vs. 
BXD29, p = 0.031; C57BL/6J vs. BXD29, p = 0.063), without being 
different on the attention parameter percentage correct responses. 
Shown are data (mean ± SEM) of the animals used for gene expres-
sion analysis (see b and material & methods). b Strain mean ± SEM 
of prefrontal cortex gene expression in BXD68 (red, n = 7), C57 
(black, n = 7), and BXD29 (blue, n = 8) for Gm28905 / Stxbp5-AS1 
(left) and Stxbp5 (right). Gm28905 / Stxbp5-AS1 is differentially 
expressed between strains, with lower expression in BXD68. Yet, 
Stxbp5 shows no differential expression. No difference in variation 
was observed. c Gene expression of Gm28905 / Stxbp5-AS1 (upper 
panels) in individual mice for which behavioral data was available 
(BXD68, n = 6; C57BL/6J, n = 7; BXD29, n = 8) correlated well with 
premature responses (motor impulsivity; left), not with accuracy 
(attention; middle), and showed a trend towards correlation with 
errors of omissions (attention; right). Stxbp5 expression (lower pan-
els) did not correlate with any of these parameters. Spearman’s rho 
(motor impulsivity, error of omissions) and Pearson’s r-values (per-
centage correct responses) are given, as well as uncorrected p-values; 
note that the Bonferroni-corrected threshold is p < 0.008. Trend lines 
are given in gray. *p < 0.05; **p < 0.01; ***p < 0.001 for post-hoc 
t-tests, where a gray line and asterisk indicates a nominal significance 
that did not survive Bonferroni correction
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impulsivity and inattention symptoms were significantly 
associated with rs12661753 (p = 1.51 × 10−5, p = 3.53 × 10−2, 
respectively). Even though the effect size is larger for hyper-
activity, we cannot claim that this is a significant difference 
(Supplemental Fig. 1). Our experiments in HEK293 cells 
showed that the lncRNA does not cause antisense inhibi-
tion of STXBP5, but may enhance STXBP5 expression. The 
role of STXBP5-AS1 with impulsivity was corroborated in 
behavioral studies in mice. The unchanged Stxbp5 mRNA 
levels in mouse strains expressing different Gm28905 levels 
is consistent with the current annotation that lack antisense 
overlap, and suggests that the lncRNA might contribute to 
impulsivity by a Stxbp5-independent mechanism. In line 
with this idea, Gm28905 expression (but not that of Stxbp5) 
correlated negatively with motor impulsivity in mice.
Our study should be viewed in the light of some strengths 
and limitations. A clear strength was the functional analy-
ses that provided a likely candidate associated with adult 
and childhood ADHD symptoms. A limitation of our study 
was the limited sample size in the SAGA meta-analysis in 
combination with the use of different phenotyping instru-
ments in the cohorts. Our results did not replicate the find-
ings from the latest GWASMA on ADHD cases and con-
trols in children (Demontis et al. 2018). Nevertheless, we 
were able to detect a strong association signal that (i) was 
also found associated in the EAGLE GWASMA (albeit less 
strong but in a pediatric population-based data) and (ii) 
shows a robust functional effect in two independent func-
tional studies corrected for multiple testing, as indicated 
on page five of the Supplementary Methods, (p-value of 
5 × 10 − 2/6 = 0.0083; correlations of two transcripts were 
tested for three parameters).
We did see some heterogeneity in the meta analysis result 
for SNP rs12661753 (Supplementary Table 3). This is partly 
due to the combination of the between-study heterogeneity 
of the measures, even for the higher correlated phenotypes, 
Fig. 3  (continued)
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the inclusion of small studies that can skew the true vari-
ances of the investigated traits and a (somewhat) low(er) 
frequency of the tested allele of the best associated SNP 
(mean MAF = 0.038; range MAF = 0.013–0.049; for details 
on each cohort see Supplementary Table 9). The aim of our 
study was to identify ADHD related genes in adults by using 
the quantitative ADHD symptom scores provided by both 
population-based and case-control samples. This means that 
some compromise had to be achieved when combining this 
information. We took care of reducing the noise by (i) per-
forming individual GWAS (per cohort, per trait) and then 
meta analyzing the results (which maximizes information 
per study including the smaller ones) and (ii) profiting from 
the strong phenotypic and genetic correlations between the 
instruments, which might have helped us maintain a better 
power to detect true association signals. Nevertheless, while 
our sample is not small (~ 15 k participants), in order to 
detect genome wide significant signals, sample sizes need 
to increase.
The genetic correlation of PCG + iPSYCH with SAGA 
should be interpreted carefully because the standard error 
was high. The fact that the PCG + iPSYCH/SAGA  rg (0.54; 
SE = 0.447) did not differ from the published  rg estimate 
between the PCG + iPSYCH GWASMA and a GWAS of 
the 23 andMe sample (0.65, SE = 0.114) (Demontis et al. 
2018) is encouraging. These correlations would confirm the 
genetic stability of ADHD in childhood and adulthood, as 
was also suggested from longitudinal modeling of twin data 
(Kan et al. 2013). The estimated genetic correlation between 
the 23 andMe and PGC + iPSYCH analyses was significant 
but lower than the genetic correlation of the EAGLE and 
PCG + iPSYCH childhood cohorts  (rg = 0.943, SE = 0.204, 
p = 3.65 × 10−6) (Demontis et al. 2018). The ADHD diagno-
sis (yes/no) in 23 andMe is based on the self-reported answer 
Fig. 3  (continued)
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to a single question about presence of a lifetime diagnosis 
of ADHD (Demontis et al. 2018) and we do not know if the 
23 andMe participants were diagnosed in childhood or as 
adults. Also, the modest and non-significant genetic corre-
lation between the SAGA and the EAGLE samples should 
be interpreted cautiously. For both samples, the SNP-based 
heritability as estimated by LDSC was low and both samples 
may suffer from their phenotypic heterogeneity as well as 
limited sample size. A further increase in GWAS sample size 
updated  rg results is still needed. These results could help 
us understand the (seemingly) different genetic correlation 
patterns between the association results estimated from the 
GWAS of adult (population-based) ADHD behavior and the 
GWAS from children. At this point, the lack of power makes 
these analyses inconclusive.
Our study shows that self-reported adult ADHD symp-
toms measured in the general population have a genetic com-
ponent and that performing population-based GWASMA 
of adult ADHD symptoms provides novel insights into 
the genetic underpinnings of hyperactivity/impulsivity 
symptoms that are a hallmark of ADHD. We were able to 
carry out functional follow-up studies which considerably 
strengthened our findings for a possible role of STXBP5-
AS1 and its mouse ortholog Gm28905 in ADHD symptom 
etiology.
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